Psoriasis treatment depends on how much skin is affected and how severely. Mild-to-moderate cases covering a small area often respond well to creams and ointments applied directly to the skin. More widespread or stubborn psoriasis typically requires light therapy, oral medications, or injectable biologics. Most people work through treatments in a stepwise fashion, starting with topicals and escalating if needed.
Topical Corticosteroids
Steroid creams and ointments remain the most common first-line treatment for mild-to-moderate psoriasis. They work by calming the overactive immune response in the skin, reducing redness, thickness, and scaling. What matters most is matching the steroid’s strength to the body area you’re treating.
Topical steroids are grouped into seven potency classes, from ultra-high (Class 1) down to the mildest (Class 7). Your doctor will choose a class based on two things: how thick the skin is in that area and how severe the plaques are. High-potency steroids are reserved for tough spots like the palms, soles, and thick plaques on the arms or legs. Low-potency steroids are used on the face, groin, armpits, and anywhere skin folds against skin, because these areas absorb more medication and are prone to thinning. Ultra-high potency formulations shouldn’t be used for more than three weeks at a stretch, and they’re never appropriate for the face or groin.
For long-term maintenance or large surface areas, lower-potency steroids are preferred to minimize side effects like skin thinning and stretch marks. Many dermatologists recommend combining a topical steroid with a retinoid cream (tazarotene) to boost effectiveness while keeping the steroid dose lower.
Newer Steroid-Free Creams
Two relatively new prescription creams offer steroid-free alternatives for mild-to-moderate plaque psoriasis, which is especially useful for sensitive areas or long-term use where steroid side effects become a concern.
Tapinarof (Vtama) is a once-daily cream that works by activating a receptor involved in skin barrier function and immune regulation. In a one-year trial, about 41% of participants achieved complete clearance of their psoriasis. Roflumilast (Zoryve) is another once-daily cream that targets inflammation through a different pathway. In two Phase 3 trials, roughly 37% to 42% of patients using the cream reached clear or almost-clear skin within eight weeks, compared to about 6% to 7% on placebo. Both options avoid the skin-thinning risks of long-term steroid use.
Scalp Psoriasis
The scalp is one of the most common and frustrating locations for psoriasis. Thick, scaly plaques can resist treatment because hair gets in the way of topical application. Medicated shampoos containing coal tar and salicylic acid help by softening and loosening scales so other treatments can penetrate. The typical approach: wet your hair with lukewarm water, work the shampoo into a lather, rub it into the scalp for about five minutes, rinse, then repeat. Using this one to two times per week helps manage buildup between other treatments.
For more stubborn scalp plaques, steroid solutions, foams, or oils designed for hairy skin are often layered on top of the descaling routine.
Phototherapy
When topicals alone aren’t enough, light therapy is often the next step. Narrowband UVB phototherapy is the most widely used form. It involves standing in a light booth that delivers a specific wavelength of ultraviolet light to slow the rapid skin cell growth driving psoriasis.
A typical course requires three sessions per week, with most people needing 20 to 36 total sessions to see significant improvement. That works out to roughly 7 to 12 weeks of regular visits. The sessions themselves are short, usually just a few minutes, but the time commitment of traveling to a clinic three times a week is the biggest practical barrier. Some dermatologists now prescribe home UVB units for patients who are good candidates, which makes the schedule more manageable.
Phototherapy can be used on its own or combined with topical treatments. It’s particularly useful for people who have widespread plaques but want to avoid systemic medications.
Oral Systemic Medications
For moderate-to-severe psoriasis that hasn’t responded to topicals or light therapy, oral medications that work throughout the body are an option. Methotrexate is the most commonly prescribed. It suppresses the overactive immune cells driving psoriasis and is taken once a week, typically at a dose between 10 and 25 mg. Because it affects the immune system, liver, and bone marrow, you’ll need regular blood work to monitor your blood cell counts, liver function, and kidney function, especially early in treatment.
A newer oral option, deucravacitinib (Sotyktu), takes a more targeted approach. It blocks a specific enzyme involved in the inflammatory signaling chain without broadly suppressing the immune system the way older drugs do. In long-term studies running up to three years, about 73% of patients maintained a 75% or greater improvement in their psoriasis. It’s taken as a daily pill, which is simpler than the injection schedule required by biologics.
Biologic Injections
Biologics are the most effective treatments available for moderate-to-severe psoriasis. These are lab-engineered proteins, delivered by injection or infusion, that block specific immune molecules responsible for psoriasis inflammation. The main targets are TNF, IL-17, IL-12/23, and IL-23. The newer IL-17 and IL-23 inhibitors tend to produce the most dramatic results. In real-world studies, over 85% of patients on these newer biologics achieved 90% skin clearance, and about 43% reached complete clearance at 12 months.
The dosing schedule varies by medication but is generally much less burdensome than phototherapy. After an initial loading period of a few doses spaced weeks apart, most biologics settle into a maintenance schedule of one injection every one to three months.
Infection Risk With Biologics
Because biologics partially suppress the immune system, infection risk is a natural concern. The data is more reassuring than many people expect. A large meta-analysis of 24 placebo-controlled trials found that at 12 to 16 weeks, the rate of serious infections was actually 0.3% in the biologic group versus 0.4% in the placebo group, with no statistically significant difference. Over longer periods of 20 to 30 weeks, the serious infection rate was slightly higher with biologics (0.9% vs. 0.4%), but this difference was not statistically significant either. In longer-term observational data, most biologics showed no meaningful increase in serious infection risk compared to older treatments like retinoids or phototherapy, though one TNF inhibitor (adalimumab) did show a higher rate in one cohort study.
Regular check-ins and screening for tuberculosis and hepatitis B before starting treatment help minimize risk. Most people on biologics don’t experience serious infections, but staying current on vaccinations and reporting fevers or prolonged illness to your doctor is standard practice.
How Treatment Decisions Are Made
Dermatologists generally follow a step-up approach. If your psoriasis covers less than about 3% to 5% of your body surface (roughly the area of three to five of your handprints), topical treatments are the starting point. If those aren’t enough after a reasonable trial of several weeks, phototherapy or a systemic medication comes next. For people with more extensive disease, joint involvement (psoriatic arthritis), or psoriasis in high-impact areas like the face, hands, or genitals, doctors may move to biologics or oral systemics sooner rather than waiting through months of topical trials.
Psoriasis is a chronic condition, so treatment is about long-term management rather than a one-time fix. Many people find a regimen that keeps their skin mostly clear and then adjust over time as their disease fluctuates or new options become available. The treatment landscape has expanded significantly in the last decade, and the percentage of patients who can achieve clear or nearly clear skin is higher now than at any point in the past.